Xenoport, Inc. (XNPT)
Q2 2012 Results Earnings Call
August 7, 2012 5:00 PM ET
Jackie Cossmon – Investor Relations
Ron Barrett – Chief Executive Officer
Bill Harris – Vice President, Finance and CFO
Vince Angotti – Executive Vice President and COO
Ravi Mehrotra – Credit Suisse
Michael Yee – RBC Capital Markets
Brian Abrahams – Wells Fargo Securities
Eric Schmidt – Cowen and Company
Juan Sanchez – Ladenburg Thalman & Company & Company
David Friedman – Morgan Stanley
Good afternoon. My name is [Temra], and I will be your conference operator today. At this time, I would like to welcome everyone to the XenoPort Second Quarter Financial Results Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question-and-answer session. (Operator Instructions)
Thank you. Ms. Cossmon. You may begin your conference.
Thank you, [Temra]. Good afternoon and thank you for joining us on the call. Here with me today are Ron Barrett, our Chief Executive Officer; Bill Harris, our Vice President of Finance and Chief Financial Officer; and Vince Angotti, our Executive Vice President and Chief Operating Officer.
Before we begin our discussion of today's news, I would like to note that the information to be discussed on this conference call and webcast, including answers to questions asked during this call will include forward-looking statements that involve risks and uncertainties, including statements related to the therapeutic and commercial potential of our product candidates, future sales of and promotional activities for gabapentin enacarbil, FDA and other regulatory authority discussions, regulatory processes and the timing of regulatory filings and actions, our current and future clinical development programs and clinical trials, the release of additional clinical trial data and the timing thereof, our clinical development efforts, potential advantages of our product candidates, our dependence on collaborative partners and matters related to our dispute with GSK.